Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial

–  ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol –  ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023
byBenzinga Newsdesk
July 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

–  ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol

–  ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts